Blepharospasm Clinical Trial
Official title:
Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
Blepharospasm (BSP) is a chronic, idiopathic, recurrent and progressive disease, which mostly occurs in both eyes. It is mainly manifested as involuntary spasm of muscles around the eyes, leading to uncontrollable narrowing or even closure of blepharospasm. Although there is no pain in BSP patients, it can cause social or psychological dysfunction, make patients feel difficult in driving, reading and working, and seriously affect the social, work and life of patients. Depression and anxiety are common and harmful mental disorders. At present, less than 40% of patients with depression can get effective treatment. Using simple and effective screening tools can effectively improve the detection rate of depression, so that patients can get timely and effective treatment. It is also an effective measure to prevent suicide. Botulinum toxin type A (BTX-A) has achieved gratifying results in the treatment of dyskinesia. It has been confirmed that BTX-A has a significant effect on BSP. The effective rate is 70% - 90%. About 50% of the patients can regain normal or near normal visual function. At present, no prospective studies have explored this association between blepharospasm and depression / anxiety, and whether BTX-A can improve this mood disorder. Therefore, our research goal is to further study the relationship between blepharospasm and depression / anxiety, sleep in a prospective way, and to determine whether BTX-A treatment will affect depression / anxiety symptoms, so as to provide more theoretical basis for clinical treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01686061 -
Blepharospasm Patient Survey for Patients With Blepharospasm
|
||
| Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
| Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
| Terminated |
NCT03263000 -
Photic Blink Reflex in People With Blepharospasm and Increased Blinking
|
||
| Completed |
NCT03938363 -
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
|
N/A | |
| Completed |
NCT02947815 -
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
|
Phase 2/Phase 3 | |
| Completed |
NCT00406367 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
|
Phase 3 | |
| Completed |
NCT00682760 -
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
|
Phase 3 | |
| Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
| Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
| Completed |
NCT04423341 -
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
|
Phase 2/Phase 3 | |
| Completed |
NCT03269123 -
A Mechanical Device for Blepharospasm
|
N/A | |
| Completed |
NCT00411255 -
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
|
Phase 2 | |
| Completed |
NCT00500799 -
Brain Changes in Blepharospasm
|
N/A | |
| Completed |
NCT00761592 -
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
|
Phase 4 | |
| Completed |
NCT00001784 -
Mexiletine for the Treatment of Focal Dystonia
|
Phase 2 | |
| Completed |
NCT03508882 -
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
|
Phase 4 | |
| Completed |
NCT01814774 -
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
|
N/A | |
| Completed |
NCT00234507 -
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
|
Phase 2 | |
| Recruiting |
NCT05618470 -
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
|
Phase 2/Phase 3 |